Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Garcia-Ribas

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Human Gene Therapy|December 31, 1997
A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma modelS A Castleden, H Chong, I Garcia-Ribas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancerJ Carles, E Esteban, M Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerS Novello, B Besse, E Felip, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Human Gene Therapy|December 31, 1997
A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma modelS A Castleden, H Chong, I Garcia-Ribas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancerJ Carles, E Esteban, M Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerS Novello, B Besse, E Felip, et al.
Pageof 1